If you are experiencing problems with alcohol or substance use , you should: Contact your GP to discuss your concerns in a confidential, non-judgemental setting Access specialist addiction services through NHS referral pathways or organisations such as Turning Point, We Are With You, or Alcoholics Anonymous Consider evidence-based treatments including cognitive behavioural therapy, motivational interviewing, and where appropriate, licensed pharmacotherapies Visit NHS support pages for alcohol support (www.nhs.uk/live-well/alcohol-advice/alcohol-support) or drug addiction help (www.nhs.uk/live-well/addiction-support/drug-addiction-getting-help) Contact FRANK (www.talktofrank.com) for confidential drug information and advice If you are already taking a GLP-1 receptor agonist for diabetes or weight management and notice changes in your substance use patterns: Inform your prescribing clinician about any changes you observe Do not alter your medication regimen without medical supervision Continue with your prescribed treatment plan for your licensed indication Seek appropriate addiction support through established pathways if needed Important safety advice: Never obtain GLP-1 medications from unregulated sources or online pharmacies without proper medical oversight These medications require careful dose titration and monitoring for adverse effects Self-medication for addiction is potentially dangerous and may delay access to effective treatments Report any suspected side effects to the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk) When to seek medical attention: Call 999 for life-threatening symptoms Contact NHS 111 for urgent medical advice when your GP is unavailable Seek immediate medical help for severe, persistent abdominal pain (potential pancreatitis) Signs of allergic reaction (rash, difficulty breathing, facial swelling) Symptoms of severe hypoglycaemia if taking other diabetes medications Any concerning symptoms or medication side effects Whilst research into GLP-1 receptor agonists and addiction continues, patients deserve access to proven, evidence-based treatments

Until then, the Phase 2 data are unambiguous: adding the glucagon receptor to the GLP-1/GIP framework appears to yield greater fat loss meaningfully, at the cost of a somewhat higher side-effect burden
This can happen initially as your body adjusts to using ketones for fuel (on keto) and the effects of the medication
It should come as no surprise that drug manufacturers have invested a lot of time and effort into diabetes treatments, as almost 12% of the U.S